Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiation for Locally Advanced Cervical Cancer
NCT00369122Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in Cervical Cancer (CC), sponsored by National Cancer Institute. Primary endpoint: Number of Subjects With Treatment-related Serious Adverse Events (SAEs) and Adverse Events (AEs) Within the First 90 Days From Treatment Start. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00369122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369122.